Hector R Wong1, Christopher J Lindsell, Patrick Lahni, Kimberly W Hart, Sebastien Gibot. 1. *Division of Critical Care Medicine, Cincinnati Children's Hospital Medical Center and Cincinnati Children's Hospital Research Foundation; and Departments of †Pediatrics; and ‡Emergency Medicine, University of Cincinnati College of Medicine, Cincinnati, OH; and §Réanimation Médicale, Hôpital Central; and ∥INSERM UMR_S 1116, Equipe TREM, Faculté de Médecine, Université de Lorraine, Nancy, France.
Abstract
PURPOSE: We previously identified interleukin 27 (IL-27) as a sepsis diagnostic biomarker in critically ill children. The current study tested the performance of IL-27 alone and in combination with procalcitonin (PCT) for diagnosing sepsis in critically ill adults. METHODS: Serum samples were made available from a prior prospective study of sepsis biomarkers in critically ill adults. The primary analysis used receiver operating characteristic curves to evaluate the performance of IL-27 and PCT. Secondary analysis explored IL-27 performance in subgroups of patients with sepsis secondary to lung and nonlung sources of infection. The net reclassification improvement was used to estimate the incremental predictive ability of IL-27 compared with PCT alone. Classification and regression tree analysis was used to generate an IL-27- and PCT-based decision tree. RESULTS: There were 145 patients with sepsis and 125 without sepsis. The receiver operating characteristic curve for IL-27 was inferior (area under the curve [AUC], 0.68; 95% confidence interval [CI], 0.62-0.75) to that of PCT (AUC, 0.84; 95% CI, 0.79-0.89). Similar findings were observed when comparing patients with a lung source of infection and those without sepsis. For sepsis patients with a nonlung source of infection, adding IL-27 to PCT improved discrimination (net reclassification improvement = 0.685; P < 0.001). The AUC for the classification and regression tree-derived decision tree was 0.92 (95% CI, 0.88-0.96) and was significantly greater than that of PCT alone. CONCLUSIONS: When used in combination with PCT, IL-27 may improve classification of critically ill adults with sepsis secondary to a nonlung source of infection.
PURPOSE: We previously identified interleukin 27 (IL-27) as a sepsis diagnostic biomarker in critically ill children. The current study tested the performance of IL-27 alone and in combination with procalcitonin (PCT) for diagnosing sepsis in critically ill adults. METHODS: Serum samples were made available from a prior prospective study of sepsis biomarkers in critically ill adults. The primary analysis used receiver operating characteristic curves to evaluate the performance of IL-27 and PCT. Secondary analysis explored IL-27 performance in subgroups of patients with sepsis secondary to lung and nonlung sources of infection. The net reclassification improvement was used to estimate the incremental predictive ability of IL-27 compared with PCT alone. Classification and regression tree analysis was used to generate an IL-27- and PCT-based decision tree. RESULTS: There were 145 patients with sepsis and 125 without sepsis. The receiver operating characteristic curve for IL-27 was inferior (area under the curve [AUC], 0.68; 95% confidence interval [CI], 0.62-0.75) to that of PCT (AUC, 0.84; 95% CI, 0.79-0.89). Similar findings were observed when comparing patients with a lung source of infection and those without sepsis. For sepsispatients with a nonlung source of infection, adding IL-27 to PCT improved discrimination (net reclassification improvement = 0.685; P < 0.001). The AUC for the classification and regression tree-derived decision tree was 0.92 (95% CI, 0.88-0.96) and was significantly greater than that of PCT alone. CONCLUSIONS: When used in combination with PCT, IL-27 may improve classification of critically ill adults with sepsis secondary to a nonlung source of infection.
Authors: Hector R Wong; Natalie Cvijanovich; Geoffrey L Allen; Richard Lin; Nick Anas; Keith Meyer; Robert J Freishtat; Marie Monaco; Kelli Odoms; Bhuvaneswari Sakthivel; Thomas P Shanley Journal: Crit Care Med Date: 2009-05 Impact factor: 7.598
Authors: Hector R Wong; Thomas P Shanley; Bhuvaneswari Sakthivel; Natalie Cvijanovich; Richard Lin; Geoffrey L Allen; Neal J Thomas; Allan Doctor; Meena Kalyanaraman; Nancy M Tofil; Scott Penfil; Marie Monaco; Mary Ann Tagavilla; Kelli Odoms; Katherine Dunsmore; Michael Barnes; Bruce J Aronow Journal: Physiol Genomics Date: 2007-03-20 Impact factor: 3.107
Authors: Stefan Pflanz; Jackie C Timans; Jeanne Cheung; Rency Rosales; Holger Kanzler; Jonathan Gilbert; Linda Hibbert; Tatyana Churakova; Marilyn Travis; Elena Vaisberg; Wendy M Blumenschein; Jeanine D Mattson; Janet L Wagner; Wayne To; Sandra Zurawski; Terrill K McClanahan; Daniel M Gorman; J Fernando Bazan; Rene de Waal Malefyt; Donna Rennick; Robert A Kastelein Journal: Immunity Date: 2002-06 Impact factor: 31.745
Authors: James L Wynn; Philip O Scumpia; Robert D Winfield; Matthew J Delano; Kindra Kelly-Scumpia; Tolga Barker; Ricardo Ungaro; Ofer Levy; Lyle L Moldawer Journal: Blood Date: 2008-06-30 Impact factor: 22.113
Authors: Stefan Wirtz; Ingrid Tubbe; Peter R Galle; Hans J Schild; Mark Birkenbach; Richard S Blumberg; Markus F Neurath Journal: J Exp Med Date: 2006-07-31 Impact factor: 14.307
Authors: Hector R Wong; Natalie Z Cvijanovich; Geoffrey L Allen; Neal J Thomas; Robert J Freishtat; Nick Anas; Keith Meyer; Paul A Checchia; Scott L Weiss; Thomas P Shanley; Michael T Bigham; Sharon Banschbach; Eileen Beckman; Kelli Harmon; Jerry J Zimmerman Journal: Am J Respir Crit Care Med Date: 2014-04-15 Impact factor: 21.405
Authors: Hector R Wong; Kathleen D Liu; Kirsten N Kangelaris; Patrick Lahni; Carolyn S Calfee Journal: J Crit Care Date: 2014-04-18 Impact factor: 3.425
Authors: Markus Bosmann; Norman F Russkamp; Birgit Strobl; Julian Roewe; Liza Balouzian; Florence Pache; Markus P Radsak; Nico van Rooijen; Firas S Zetoune; J Vidya Sarma; Gabriel Núñez; Mathias Müller; Peter J Murray; Peter A Ward Journal: J Immunol Date: 2014-10-27 Impact factor: 5.422
Authors: F Mearelli; D Orso; N Fiotti; N Altamura; A Breglia; M De Nardo; I Paoli; M Zanetti; C Casarsa; G Biolo Journal: Infection Date: 2014-08-11 Impact factor: 3.553